EP3679061A4 - Verfahren zur prognose von brustläsionen im frühstadium - Google Patents

Verfahren zur prognose von brustläsionen im frühstadium Download PDF

Info

Publication number
EP3679061A4
EP3679061A4 EP18854610.5A EP18854610A EP3679061A4 EP 3679061 A4 EP3679061 A4 EP 3679061A4 EP 18854610 A EP18854610 A EP 18854610A EP 3679061 A4 EP3679061 A4 EP 3679061A4
Authority
EP
European Patent Office
Prior art keywords
methods
early stage
stage breast
breast lesions
prognosing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18854610.5A
Other languages
English (en)
French (fr)
Other versions
EP3679061A1 (de
Inventor
Georg F. Weber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Cincinnati
Original Assignee
University of Cincinnati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Cincinnati filed Critical University of Cincinnati
Publication of EP3679061A1 publication Critical patent/EP3679061A1/de
Publication of EP3679061A4 publication Critical patent/EP3679061A4/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Data Mining & Analysis (AREA)
  • Primary Health Care (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP18854610.5A 2017-09-06 2018-09-06 Verfahren zur prognose von brustläsionen im frühstadium Pending EP3679061A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762554712P 2017-09-06 2017-09-06
PCT/US2018/049684 WO2019051041A1 (en) 2017-09-06 2018-09-06 EARLY PROGNOSTIC METHODS OF MAMMARY LESIONS

Publications (2)

Publication Number Publication Date
EP3679061A1 EP3679061A1 (de) 2020-07-15
EP3679061A4 true EP3679061A4 (de) 2021-06-09

Family

ID=65635209

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18854610.5A Pending EP3679061A4 (de) 2017-09-06 2018-09-06 Verfahren zur prognose von brustläsionen im frühstadium

Country Status (3)

Country Link
US (1) US11791043B2 (de)
EP (1) EP3679061A4 (de)
WO (1) WO2019051041A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230203193A1 (en) * 2020-06-03 2023-06-29 Georg F. Weber Isolated antibodies and fragments thereof with specificity for osteopontin-c

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7205398B2 (en) * 2002-05-24 2007-04-17 Schering-Plough Animal Health Corporation Eta-1 gene and methods for use
ATE547709T1 (de) * 2005-11-14 2012-03-15 Metamol Theranostics Llc Tumorinvasionsfördernde peptidsequenz
US7867725B2 (en) * 2006-10-30 2011-01-11 Maine Medical Center Monoclonal antibodies against osteopontin
ES2538362T3 (es) * 2007-10-16 2015-06-19 Ventana Medical Systems, Inc. Clasificación, estadificación y pronóstico del cáncer mediante el uso de osteopontina-C
CA2992282A1 (en) * 2015-07-14 2017-01-19 Atossa Genetics Inc. Transpapillary methods and compositions for treating breast disorders
WO2017117182A1 (en) * 2015-12-29 2017-07-06 Board Of Regents, The University Of Texas System Inhibition of p38 mapk for the treatment of cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KIMBERLY COLE ET AL: "Biologic characteristics of premalignant breast disease", CANCER BIOMARKERS : SECTION A OF DISEASE MARKERS, 1 January 2010 (2010-01-01), Netherlands, pages 177 - 192, XP055264033, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3432637/pdf/nihms-388297.pdf> [retrieved on 20160411], DOI: 10.3233/CBM-2011-0187 *
MARTA SANTISTEBAN ET AL: "Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplasia", BREAST CANCER RESEARCH AND TREATMENT, KLUWER ACADEMIC PUBLISHERS, BO, vol. 121, no. 2, 23 September 2009 (2009-09-23), pages 431 - 437, XP019814360, ISSN: 1573-7217 *
MIRKIN SEBASTIAN ET AL: "Selective estrogen receptor modulators (SERMs): A review of clinical data", MATURITAS, ELSEVIER, AMSTERDAM, NL, vol. 80, no. 1, 23 October 2014 (2014-10-23), pages 52 - 57, XP029116950, ISSN: 0378-5122, DOI: 10.1016/J.MATURITAS.2014.10.010 *
WALASZEK KINGA ET AL: "Breast cancer risk in premalignant lesions: osteopontin splice variants indicate prognosis", BRITISH JOURNAL OF CANCER, NATURE PUBLISHING GROUP, GB, vol. 119, no. 10, 24 October 2018 (2018-10-24), pages 1259 - 1266, XP036639155, ISSN: 0007-0920, [retrieved on 20181024], DOI: 10.1038/S41416-018-0228-1 *

Also Published As

Publication number Publication date
WO2019051041A1 (en) 2019-03-14
US11791043B2 (en) 2023-10-17
US20200271652A1 (en) 2020-08-27
EP3679061A1 (de) 2020-07-15

Similar Documents

Publication Publication Date Title
EP3524689A4 (de) Verfahren zur prognose von brustkrebspatienten
EP3443066A4 (de) Verfahren zum frühen nachweis von krebs
EP3261646A4 (de) Reduktion von fettgewebe
EP3177739A4 (de) Mikro-rna-biomarker zur diagnose von magenkrebs
EP3516585A4 (de) Mapping von arteriellen verkalkungen in der brust
EP3227686A4 (de) Multiplexierte immunhistochemie-assays zur diagnose und behandlung von krebs
EP3298145A4 (de) Verfahren zur diagnose von brustkrebs
WO2015148979A8 (en) Compositions and methods related to diagnosis of prostate cancer
EP3365063A4 (de) Verfahren zur bewertung einer probe mit tumorgewebe
EP3630293A4 (de) Biomarker zur diagnose von lungenkrebs
EP3565542A4 (de) Polymorphe formen von rad1901-2hcl
EP3164711A4 (de) Spezifische biomarker zur nicht-invasiven diagnose von leberkrebs
EP3426241A4 (de) Verfahren zur diagnose von krebs
EP3668876A4 (de) Polymorphe formen von tg02
EP3574113A4 (de) Verbesserte verfahren zur beurteilung des risikos des auftretens von brustkrebs
EP3286340A4 (de) Metagenomische zusammensetzungen und verfahren für den nachweis von brustkrebs
EP3189333A4 (de) Krebsdiagnose
EP3695015A4 (de) Verfahren zur beurteilung des risikos des auftretens von brustkrebs
EP3092027A4 (de) Transpapilläre verfahren und zusammensetzungen zur diagnose und behandlung von brusterkrankungen
EP3347051A4 (de) Auf sequenzierung ausgerichtete auswahl von tumortheranostika
EP3679061A4 (de) Verfahren zur prognose von brustläsionen im frühstadium
EP3200700A4 (de) Biopsiekit und verfahren zur entfernung eines teils eines zielgewebes
EP3635402A4 (de) Biomarker einer krankheit
EP3189332A4 (de) Biomarker zur vorhersage von brustkrebs
IL268274A (en) Methods for diagnosing malignant diseases

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200306

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20210511

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/52 20060101AFI20210504BHEP

Ipc: C07K 16/18 20060101ALI20210504BHEP

Ipc: C07K 16/24 20060101ALI20210504BHEP

Ipc: C12Q 1/68 20180101ALI20210504BHEP

Ipc: G01N 33/53 20060101ALI20210504BHEP

Ipc: G01N 33/574 20060101ALI20210504BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20240322

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS